MitraClip: Impact of Sinus Rhythm and Heart Rate

MitraClip: Impact of Sinus Rhythm and Heart RateCourtesy of Dr. Carlos Fava.

Atrial fibrillation (AF) and fast heart rate (>70 lpm) have been shown to increase the risk of mitral valve repair surgery. The MitraClip has shown benefits in high risk patients, but its relation to abnormal heart rhythm has not yet been established.

 

760 patients were analyzed; 315 (52.4%) presented sinus rhythm (SR) and 286 (47.6%) atrial fibrillation. In the SR group, 365 patients (46.8%) presented a ≤70 lpm heart rate, and 404 (53.2%), a >70 lpm heart rate.

 

AF patients were older, had mild ventricular deterioration, and larger left auricular diameter. On the other hand, SR patients more often presented a history of MI, diabetes, (especially those with <70 heart rate), severe left ventricular function deterioration and increased end-diastolic volume.

 

Procedural success was 97.5%, with no significant differences between subgroups as regards:

  • procedural time
  • fluoroscopy
  • number of clips implanted
  • intra-procedural complications

 

There were no differences as regards in hospital stay, though SR patients presenting <70 lpm heart rate saw a shorter stay.

 

At 30 days, there were no differences in mortality (SR 3%, AF 5.8%, SR≤70 4.3% and SR>70 4.5%). The only mortality predictor was a >2 mg/dl creatinine value. Functional class saw sustained improvement across all subgroups.

 

Conclusion

These registry data (comparing a large “real world” unselected series of patients with mitral regurgitation receiving MitraClip) suggest that this intervention is safe and effective and that it reduces mitral regurgitation in most patients, regardless of baseline sinus rhythm or heart rate. While at 12 months survival rate was higher for those in SR, MACE and clinical improvement was no different between the groups.

 

Editorial Comment

This analysis of the German registry shows the MitraClip has benefits for high risk patients regardless of sinus rhythm or heart rate, as opposed to mitral valve surgery.

 

It is important to intervene before kidney failure, since this has a negative impact on results.

 

We need to evaluate these outcomes against those of larger studies.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

Original Title: Effects of atrial fibrillation and heart rateo in percutaneous mitral valve repair with MitraClip: results from the TRAnscatheter Mitral valve Intervention (TRAMI) registry.

Reference: Alexnader Jabs et al. EuroIntervention 2017;12:1697-1705.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...